Date:2/10/2010

485 70.3% ------- ------- Gross Profit 70,278 29.7% 73,743 29.5% Operating Expenses Selling, General and Administrative Expenses 35,711 15.0% 40,521 16.2% Research and Development Expenses 7,929 3.4% 7,590 3.0% Restructuring Expenses - 0.0% 4,695 1.9% Strategic Alternative Costs - 0.0% 1,515 0.6% ------- ------- Total Operating Expenses 43,640 18.4% 54,321 21.7% ------- ------- Operating Profit 26,638 11.3% 19,422 7.8% Other Expenses/(Income): Interest Expense, net 4,634 2.0% 3,668 1.5% Other (Income)/Expense, net (641) -0.3% 754 0.3% ------- ------- Income Before Income Taxes 22,645 9.6% 15,000 6.0% Provision for Income Taxes 12,253 5.2% 7,071 2.8% ------- ------- Net Income
'/>"/>

SOURCE Cambrex Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results